Tecentriq/Avastin combo hits progression-free survival target

11th December 2017 Uncategorised 0

Roche unit Genentech has announced that a Phase III study assessing a combination of Tecentriq and Avastin for advanced or metastatic renal cell carcinoma achieved its co-primary endpoint of progression-free survival.

More: Tecentriq/Avastin combo hits progression-free survival target
Source: News